Advancements and Personalization of Breast Cancer Treatment Strategies in Radiation Therapy

  • Meena S. MoranEmail author
Part of the Cancer Treatment and Research book series (CTAR, volume 173)


Significant technologic advances in radiation treatment delivery now allow for more personalized delivery considerations which incorporate individual patient characteristics (such as tumor location and patient anatomy) and more precise delivery in the breast conservation or post-mastectomy setting. The combined advancements with other treatment modalities (i.e., systemic therapy, surgical management) have had direct effects on local-regional management and outcomes such that currently, local-regional relapses after definitive treatment for localized disease are now rarely experienced. Recent advances in the radiation therapy field have come from careful patient selection for a variety of three-dimensional treatment delivery techniques and alternatives to conventional tangential radiation. These advances have been demonstrated to diminished acute/long-term toxicity, minimized dose to surrounding normal tissue structures such as the heart and lung, and ultimately result in an improvement in the therapeutic ratio for radiation treatment. This chapter discusses recent radiation innovations and appropriate patient selection for their application, for a more personalized approach to radiation therapy for breast cancer patients.


Breast cancer Radiation therapy Techniques Deep inspiration breath hold Breast conservation therapy Regional nodal radiation 


  1. 1.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241CrossRefPubMedGoogle Scholar
  2. 2.
    Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens M-R, Van Limbergen E et al (2012) Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 13(4):412–419CrossRefPubMedGoogle Scholar
  3. 3.
    Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ et al (2003) Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98(4):697–702CrossRefPubMedGoogle Scholar
  4. 4.
    Simone N, Dan T, Shih J, Smith S, Sciuto L, Lita E et al (2012) Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat 132(1):197–203CrossRefPubMedGoogle Scholar
  5. 5.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(16):1227–1232CrossRefPubMedGoogle Scholar
  6. 6.
    American Cancer Society (2015) Breast cancer facts & figures 2015-2016. American Cancer Society I, AtlantaGoogle Scholar
  7. 7.
    Gradishar WJ, Hansen NM, Susnik B (2009) Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice. Clin Adv Hematol Oncol H&O 7(4):1–7Google Scholar
  8. 8.
    Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691CrossRefPubMedGoogle Scholar
  9. 9.
    Bouganim N, Tsvetkova E, Clemons M, Amir E (2013) Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat 139(2):603–606CrossRefPubMedGoogle Scholar
  10. 10.
    Early Breast Cancer Trialists’ Collaborative (2011) G. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRefGoogle Scholar
  11. 11.
    Garcia-Etienne CA, Tomatis M, Heil J, Danaei M, Rageth CJ, Marotti L et al (2013) Fluctuating mastectomy rates across time and geography. Ann Surg Oncol 20(7):2114–2116CrossRefPubMedGoogle Scholar
  12. 12.
    Farrow DC, Hunt WC, Samet JM (1992) Geographic variation in the treatment of localized breast cancer. N Engl J Med 326(17):1097–1101CrossRefPubMedGoogle Scholar
  13. 13.
    Gabriel G, Barton M, Delaney GP (2015) The effect of travel distance on radiotherapy utilization in NSW and ACT. Radiother Oncol 117(2):386–389 Google Scholar
  14. 14.
    Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A et al (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol 120(1):114–118CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rowe B, Moran MS (2011) Accelerated partial breast irradiation and hypofractionated whole breast radiation. US Oncol Hematol 7(1):31–37Google Scholar
  16. 16.
    Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341CrossRefPubMedGoogle Scholar
  17. 17.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520CrossRefPubMedGoogle Scholar
  18. 18.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094CrossRefPubMedGoogle Scholar
  19. 19.
    Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107Google Scholar
  20. 20.
    Group FT, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P et al (2011) First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol 100(1):93–100Google Scholar
  21. 21.
    Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107CrossRefPubMedGoogle Scholar
  22. 22.
    Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS et al (2010) Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol PhysGoogle Scholar
  23. 23.
    The Choosing Wisely campaign: American Society for Radiation Oncology 10 Things Physicians and Patients Should Question (n.d.) Retrieved April 7, from
  24. 24.
    Vicini FA, Kestin LL, Goldstein NS (2004) Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis. Int J Radiat Oncol Biol Phys 60(3):722–730CrossRefPubMedGoogle Scholar
  25. 25.
    B Fisher, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg 18(1):63–69Google Scholar
  26. 26.
    Clark RM, McCulloch PB, Levine MN, Lipa M, Wilkinson RH, Mahoney LJ et al (1992) Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary disection for node-negative breast cancer. J Natl Cancer Inst 84(9):683–689CrossRefPubMedGoogle Scholar
  27. 27.
    Smith TE, Lee D, Turner BC, Carter D, Haffty BG (2000) True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48(5):1281–1289CrossRefPubMedGoogle Scholar
  28. 28.
    Liljegren G, Holmberg L, Adami HO, Westman G, Graffman S, Bergh J (1994) Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J Natl Cancer Inst 86(9):717–722CrossRefPubMedGoogle Scholar
  29. 29.
    Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M et al (1993) Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 328(22):1587–1591CrossRefPubMedGoogle Scholar
  30. 30.
    Polgár C, Major T, Lövey K et al (2008) Hungarian experience on partial breast irradiation versus whole breast irradiation: 12-year results of a phase II trial and updated results of a randomized study. Brachytherapy 7:91–92[Abstract]Google Scholar
  31. 31.
    Vicini FA, Horwitz EM, Lacerna MD, Dmuchowski CF, Brown DM, White J et al (1997) Long-term outcome with interstitial brachytherapy in the management of patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 37(4):845–852CrossRefPubMedGoogle Scholar
  32. 32.
    Vicini FA, Arthur DW (2005) Breast brachytherapy: North American experience. Semin Radiat Oncol 15(2):108–115CrossRefPubMedGoogle Scholar
  33. 33.
    Khan AJ, Arthur D, Vicini F, Beitsch P, Kuerer H, Goyal S et al (2012) Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol 19(5):1477–1483CrossRefPubMedGoogle Scholar
  34. 34.
    Vicini F, Beitsch PD, Quiet CA, Keleher AJ, Garcia D, Snider HC Jr et al (2008) Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 112(4):758–766CrossRefPubMedGoogle Scholar
  35. 35.
    Vicini FA, Beitsch PD, Quiet CA, Keleher A, Garcia D, Snider HC et al (2005) First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer 104(6):1138–1148CrossRefPubMedGoogle Scholar
  36. 36.
    Vicini F, Winter K, Wong J, Pass H, Rabinovitch R, Chafe S et al (2010) Initial Efficacy Results of RTOG 0319: Three-Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I/II Breast Carcinoma. Int J Radiat Oncol Biol Phys 77(4):1120–1127Google Scholar
  37. 37.
    Julian TB, JP C, FA V et al (2011) Early toxicity results with 3D conformal external beam (CEBT) from the NSABP B39/RTOG 0413 accelerated partial breast irradiation trial. J Clin Oncol 29:82s (suppl; abstr 1011)Google Scholar
  38. 38.
    Olivotto IA, Whelan TJ, Parpia S, Kim D-H, Berrang T, Truong PT et al (2013) Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 31(32):4038–4045CrossRefPubMedGoogle Scholar
  39. 39.
    Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, Price LL et al (2009) Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 75(5):1290–1296CrossRefPubMedGoogle Scholar
  40. 40.
    Jagsi R, Ben-David MA, Moran JM, Marsh RB, Griffith KA, Hayman JA et al (2010) Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys 76(1):71–78CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Moran MS, Truong PT (2014) Intraoperative accelerated partial breast irradiation: caution still warranted. Int J Radiat Oncol Biol Phys 89(3):496–498Google Scholar
  42. 42.
    Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C et al (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14(13):1269–1277CrossRefPubMedGoogle Scholar
  43. 43.
    Veronesi U, Orecchia R, Luini A, Galimberti V, Zurrida S, Intra M et al (2010) Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat 124(1):141–151CrossRefPubMedGoogle Scholar
  44. 44.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613CrossRefPubMedGoogle Scholar
  45. 45.
    Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH et al (2009) Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg 209(2):269–277CrossRefPubMedGoogle Scholar
  46. 46.
    Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM et al (2016) Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat OncolGoogle Scholar
  47. 47.
    Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J et al (2014) Society of surgical oncology-American society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin OncolGoogle Scholar
  48. 48.
    Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B et al (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351(10):971–977CrossRefPubMedGoogle Scholar
  49. 49.
    Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 16(3):266–273CrossRefPubMedGoogle Scholar
  50. 50.
    Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Blamey RW, Bates T, Chetty U, Duffy SW, Ellis IO, George D et al (2013) Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 49(10):2294–2302CrossRefPubMedGoogle Scholar
  52. 52.
    Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A et al (2016) Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14(3):324–354CrossRefPubMedGoogle Scholar
  53. 53.
    Palta M, Palta P, Bhavsar NA, Horton JK, Blitzblau RC (2015) The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. Cancer 121(2):188–193CrossRefPubMedGoogle Scholar
  54. 54.
    Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR et al (2016) Society of surgical oncology-American society for radiation oncology-American Society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Ann Surg OncolGoogle Scholar
  55. 55.
    Wärnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K et al (2014) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol 32(32):3613–3618CrossRefPubMedGoogle Scholar
  56. 56.
    Donker M, Litière S, Werutsky G, Julien J-P, Fentiman IS, Agresti R et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin OncolGoogle Scholar
  57. 57.
    Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12(1):21–29CrossRefPubMedGoogle Scholar
  58. 58.
    Wapnir I, Dignam J, Fisher B, Mamounas E, Anderson S, Julian T et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Moran MS (2015) Ductal Carcinoma in situ and relevant endpoints for omission of standard treatments: are we there yet? ASCO Post 2015;Dec 25, 2015.
  60. 60.
    McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL et al (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin OncolGoogle Scholar
  61. 61.
    Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC et al (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036CrossRefPubMedGoogle Scholar
  62. 62.
    Wong JS, Chen YH, Gadd MA, Gelman R, Lester SC, Schnitt SJ et al (2014) Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat 143(2):343–350CrossRefPubMedGoogle Scholar
  63. 63.
    Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE et al (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(32):5319–5324CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS et al (2015) Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin OncolGoogle Scholar
  65. 65.
    Rakovitch E, Nofech-Mozes S, Hanna W, Baehner F, Saskin R, Butler S et al (2015) A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152(2):389–398CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S et al (2010) Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 28(23):3762–3769CrossRefPubMedGoogle Scholar
  67. 67.
    EBCTCG (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. JNCI Monogr 2010(41):162–177Google Scholar
  68. 68.
    Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N et al (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—the LORD study. Eur J Cancer 51(12):1497–1510CrossRefPubMedGoogle Scholar
  69. 69.
    Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JMS, Brookes C et al (2015) Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 51(16):2296–2303CrossRefPubMedGoogle Scholar
  70. 70.
    Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337(14):956–962CrossRefPubMedGoogle Scholar
  71. 71.
    Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337(14):949–955CrossRefPubMedGoogle Scholar
  72. 72.
    Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M et al (1999) Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353(9165):1641–1648CrossRefPubMedGoogle Scholar
  73. 73.
    Group EBCTC (1995) Effects of radiotherapy and surgery in early breast cancer—an overview of the randomized trials. N Engl J Med 333(22):1444–1456Google Scholar
  74. 74.
    Early Breast Cancer Trialists’ Collaborative (2000) G. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355(9217):1757–1770CrossRefGoogle Scholar
  75. 75.
    Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE et al (2001) Postmastectomy radiotherapy: clinical practice guidelines of the american society of clinical oncology. J Clin Oncol 19(5):1539–1569CrossRefPubMedGoogle Scholar
  76. 76.
    Carlson RW, McCormick B (2005) Update: NCCN breast cancer clinical practice guidelines. J Natl Compr Cancer Netw JNCCN 3(Suppl 1):S7–S11Google Scholar
  77. 77.
    EBCTCG (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. LancetGoogle Scholar
  78. 78.
    Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY et al (2016) Postmastectomy radiotherapy: an american society of clinical oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin OncolGoogle Scholar
  79. 79.
    Louis-Sylvestre C, Clough K, Asselain B, Vilcoq JR, Salmon RJ, Fß Campana et al (2004) Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? results of a randomized study with 15 years of follow-up. J Clin Oncol 22(1):97–101CrossRefPubMedGoogle Scholar
  80. 80.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA et al (2014) Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin OncolGoogle Scholar
  82. 82.
    Giuliano Aea (2016) Ten-year survival results of ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance). J Clin Oncol 34 (suppl; abstr 1007)Google Scholar
  83. 83.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373(4):317–327CrossRefPubMedGoogle Scholar
  85. 85.
    Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373(4):307–316CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Budach W, Bolke E, Kammers K, Gerber PA, Nestle-Kramling C, Matuschek C (2015) Adjuvant radiation therapy of regional lymph nodes in breast cancer—a meta-analysis of randomized trials—an update. Radiat Oncol 10:258CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J et al (2013) Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys 86(5):860–866CrossRefPubMedGoogle Scholar
  88. 88.
    Thorsen LB, Offersen BV, Dano H, Berg M, Jensen I, Pedersen AN et al (2016) DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol 34(4):314–320CrossRefPubMedGoogle Scholar
  89. 89.
    Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al (2013) IBCSG 23-01 randomised controlled trial comparing axillary dissection versus no axillary dissection in patients with sentinel node micrometastases. Lancet Oncol 14(4):297–305CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106CrossRefPubMedGoogle Scholar
  91. 91.
    Hall EJ, Giaccia AJ (2012) Radiobiology for the radiologist (edition 7E, 2012). 6th edn. Philadelphia: Lippincott Williams & Wilkins. ix, 546 ppGoogle Scholar
  92. 92.
    Bentzen SM, Turesson I, Thames HD (1990) Fractionation sensitivity and latency of telangiectasia after postmastectomy radiotherapy: a graded-response analysis. Radiother Oncol 18:95–106Google Scholar
  93. 93.
    Porock D, Kristjanson L, Nikoletti S, Cameron F, Pedler P (1998) Predicting the severity of radiation skin reactions in women with breast cancer. Oncol Nurs Forum 25(6):1019–1029PubMedGoogle Scholar
  94. 94.
    Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS (2002) ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52(3):606–613CrossRefPubMedGoogle Scholar
  95. 95.
    Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC et al (2011) The Cambridge breast intensity-modulated radiotherapy trial: patient- and treatment-related factors that influence late toxicity. Clin Oncol 23(10):662–673CrossRefGoogle Scholar
  96. 96.
    Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W et al (2008) A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26(13):2085–2092CrossRefPubMedGoogle Scholar
  97. 97.
    Mukesh MB, Barnett GC, Wilkinson JS, Moody AM, Wilson C, Dorling L et al (2013) Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 31(36):4488–4495CrossRefPubMedGoogle Scholar
  98. 98.
    Moran MS, Haffty BG (2009) Radiation techniques and toxicities for locally advanced breast cancer. Semin Radiat Oncol 19(4):244–255CrossRefPubMedGoogle Scholar
  99. 99.
    Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56(1):83–88CrossRefPubMedGoogle Scholar
  100. 100.
    Lin LL, Vennarini S, Dimofte A, Ravanelli D, Shillington K, Batra S et al (2015) Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer. Acta Oncol 54(7):1032–1039CrossRefPubMedGoogle Scholar
  101. 101.
    Smith BD, Pan IW, Shih YC, Smith GL, Harris JR, Punglia R et al (2011) Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103(10):798–809CrossRefPubMedGoogle Scholar
  102. 102.
    Kurtz JM, Spitalier JM (1990) Local recurrence after breast-conserving surgery and radiotherapy: what have we learned? Int J Radiat Oncol Biol Phys 19(4):1087–1089CrossRefPubMedGoogle Scholar
  103. 103.
    Cammarota F, Giugliano FM, Iadanza L, Cutillo L, Muto M, Toledo D et al (2014) Hypofractionated breast cancer radiotherapy. Helical tomotherapy in supine position or classic 3D-conformal radiotherapy in prone position: which is better? Anticancer Res 34(3):1233–1238PubMedGoogle Scholar
  104. 104.
    Goodman KA, Hong L, Wagman R, Hunt MA, McCormick B (2004) Dosimetric analysis of a simplified intensity modulation technique for prone breast radiotherapy. Int J Radiat Oncol Biol Phys 60(1):95–102CrossRefPubMedGoogle Scholar
  105. 105.
    Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD (2012) Prone vs supine positioning for breast cancer radiotherapy. JAMA 308(9):861–863CrossRefPubMedGoogle Scholar
  106. 106.
    Raj KA, Evans ES, Prosnitz RG, Quaranta BP, Hardenbergh PH, Hollis DR et al (2006) Is there an increased risk of local recurrence under the heart block in patients with left-sided breast cancer? Cancer J 12(4):309–317CrossRefPubMedGoogle Scholar
  107. 107.
    Lu HM, Cash E, Chen MH, Chin L, Manning WJ, Harris J et al (2000) Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study. Int J Radiat Oncol Biol Phys 47(4):895–904CrossRefPubMedGoogle Scholar
  108. 108.
    Korreman SS, Pedersen AN, Nottrup TJ, Specht L, Nystrom H (2005) Breathing adapted radiotherapy for breast cancer: comparison of free breathing gating with the breath-hold technique. Radiother Oncol J Euro Soc Ther Radiol Oncol 76(3):311–318CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Therapeutic Radiology, Yale Radiation Therapy ProgramYale University School of MedicineNew HavenUSA

Personalised recommendations